This randomized Phase 3 clinical trial found that adding cetuximab to standard mFOLFOX6 adjuvant chemotherapy did not improve either overall survival or disease-free survival in patients with resected stage III colon cancer, including those with wild-type KRAS tumors.
This randomized Phase 3 clinical trial found that adding cetuximab to standard mFOLFOX6 adjuvant chemotherapy did not improve either overall survival or disease-free survival in patients with resected stage III colon cancer, including those with wild-type KRAS tumors.
Cetuximab Adds No Benefit to Adjuvant Chemotherapy in Stage III Colon Cancer
May 1, 2012